Mastering MRD for Prognosis and Treatment in ALL

Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care.

During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy.

This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.